Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16162831 | 0.90 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL14932240 | 0.90 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16162828 | 0.90 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL14932229 | 0.85 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL13028110 | 0.83 | KCNJ1 (0.73) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2897307 | 0.82 | KCNJ1 (0.86) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL13076918 | 0.80 | KCNJ1 (0.83) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL13028099 | 0.78 | KCNJ1 (0.84) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20881116 | 0.77 | KCNJ1 (0.72) | KCNJ1KCNH2 | |
| SCHEMBL16162829 | 0.76 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139585-B2 | Inhibitors of the Renal Outer Medullary Potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | claimed |
| US-20140309213-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-10-16 | — | — | US | claimed |
| EP-2773199-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2013066714-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | claimed |
| US-9139585-B2 | Inhibitors of the Renal Outer Medullary Potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139585-B2 | Inhibitors of the Renal Outer Medullary Potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139585-B2 | Inhibitors of the Renal Outer Medullary Potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140309213-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-10-16 | — | — | US | disclosed |
| US-20140309213-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-10-16 | — | — | US | disclosed |
| US-20140309213-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-10-16 | — | — | US | disclosed |
| EP-2773199-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013066714-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013066714-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309213-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ2, KCNJ11, KCNJ1 | KCNJ1 3/4885KCNH2 4/4885ACHE 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.